These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25595685)

  • 1. 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate.
    Bond S; Draffan AG; Fenner JE; Lambert J; Lim CY; Lin B; Luttick A; Mitchell JP; Morton CJ; Nearn RH; Sanford V; Anderson KH; Mayes PA; Tucker SP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):976-81. PubMed ID: 25595685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1.
    Bond S; Draffan AG; Fenner JE; Lambert J; Lim CY; Lin B; Luttick A; Mitchell JP; Morton CJ; Nearn RH; Sanford V; Stanislawski PC; Tucker SP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):969-75. PubMed ID: 25595682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo.
    Yu KL; Wang XA; Civiello RL; Trehan AK; Pearce BC; Yin Z; Combrink KD; Gulgeze HB; Zhang Y; Kadow KF; Cianci CW; Clarke J; Genovesi EV; Medina I; Lamb L; Wyde PR; Krystal M; Meanwell NA
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1115-22. PubMed ID: 16368233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor.
    Cianci C; Meanwell N; Krystal M
    J Antimicrob Chemother; 2005 Mar; 55(3):289-92. PubMed ID: 15681582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate.
    Henderson EA; Alber DG; Baxter RC; Bithell SK; Budworth J; Carter MC; Chubb A; Cockerill GS; Dowdell VC; Fraser IJ; Harris RA; Keegan SJ; Kelsey RD; Lumley JA; Stables JN; Weerasekera N; Wilson LJ; Powell KL
    J Med Chem; 2007 Apr; 50(7):1685-92. PubMed ID: 17341059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses.
    Budge PJ; Graham BS
    J Antimicrob Chemother; 2004 Aug; 54(2):299-302. PubMed ID: 15254023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-benzimidazole containing inhibitors of respiratory syncytial virus.
    Pryde DC; Tran TD; Gardner I; Bright H; Stupple P; Galan S; Alsop L; Watson L; Middleton DS; Dayal S; Platts M; Murray EJ; Parkinson T; Webster R
    Bioorg Med Chem Lett; 2013 Feb; 23(3):827-33. PubMed ID: 23265891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two novel fusion inhibitors of human respiratory syncytial virus.
    Lundin A; Bergström T; Bendrioua L; Kann N; Adamiak B; Trybala E
    Antiviral Res; 2010 Dec; 88(3):317-24. PubMed ID: 20965215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a high-throughput replicon assay for the identification of respiratory syncytial virus inhibitors.
    Tiong-Yip CL; Plant H; Sharpe P; Fan J; Rich K; Gorseth E; Yu Q
    Antiviral Res; 2014 Jan; 101():75-81. PubMed ID: 24246168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anti-RSV dianionic dendrimer-like compounds: design, synthesis and biological evaluation.
    Gazumyan A; Mitsner B; Ellestad GA
    Curr Pharm Des; 2000 Mar; 6(5):525-46. PubMed ID: 10788595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Throughput Hit Screening Cascade to Identify Respiratory Syncytial Virus (RSV) Inhibitors.
    Plant H; Stacey C; Tiong-Yip CL; Walsh J; Yu Q; Rich K
    J Biomol Screen; 2015 Jun; 20(5):597-605. PubMed ID: 25656237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity.
    Wang XA; Cianci CW; Yu KL; Combrink KD; Thuring JW; Zhang Y; Civiello RL; Kadow KF; Roach J; Li Z; Langley DR; Krystal M; Meanwell NA
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4592-8. PubMed ID: 17576060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico structure-based design and synthesis of novel anti-RSV compounds.
    Cancellieri M; Bassetto M; Widjaja I; van Kuppeveld F; de Haan CA; Brancale A
    Antiviral Res; 2015 Oct; 122():46-50. PubMed ID: 26259810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
    Golankiewicz B; Januszczyk P; Ikeda S; Balzarini J; De Clercq E
    J Med Chem; 1995 Sep; 38(18):3558-65. PubMed ID: 7658442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5).
    Elliott MB; Tebbey PW; Pryharski KS; Scheuer CA; Laughlin TS; Hancock GE
    J Med Virol; 2004 Jun; 73(2):300-8. PubMed ID: 15122808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action.
    Sudo K; Miyazaki Y; Kojima N; Kobayashi M; Suzuki H; Shintani M; Shimizu Y
    Antiviral Res; 2005 Feb; 65(2):125-31. PubMed ID: 15708639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.
    Yan D; Lee S; Thakkar VD; Luo M; Moore ML; Plemper RK
    Proc Natl Acad Sci U S A; 2014 Aug; 111(33):E3441-9. PubMed ID: 25092342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-aryl-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ols. A novel class of anorectic agents.
    Aeberli P; Eden P; Gogerty JH; Houlihan WJ; Penberthy C
    J Med Chem; 1975 Feb; 18(2):177-82. PubMed ID: 804553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
    Mackman RL; Sangi M; Sperandio D; Parrish JP; Eisenberg E; Perron M; Hui H; Zhang L; Siegel D; Yang H; Saunders O; Boojamra C; Lee G; Samuel D; Babaoglu K; Carey A; Gilbert BE; Piedra PA; Strickley R; Iwata Q; Hayes J; Stray K; Kinkade A; Theodore D; Jordan R; Desai M; Cihlar T
    J Med Chem; 2015 Feb; 58(4):1630-43. PubMed ID: 25574686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship.
    Bonfanti JF; Doublet F; Fortin J; Lacrampe J; Guillemont J; Muller P; Queguiner L; Arnoult E; Gevers T; Janssens P; Szel H; Willebrords R; Timmerman P; Wuyts K; Janssens F; Sommen C; Wigerinck P; Andries K
    J Med Chem; 2007 Sep; 50(19):4572-84. PubMed ID: 17722899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.